Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jun;9(3):1099-1111.
doi: 10.1007/s13300-018-0421-5. Epub 2018 Apr 11.

Adherence to Basal Insulin Therapy Among People with Type 2 Diabetes: A Retrospective Cohort Study of Costs and Patient Outcomes

Magaly Perez-Nieves  1 , Kristina S Boye  1 , Jacek Kiljanski  1 , Dachung Cao  1 , Maureen J Lage  2
Affiliations

Adherence to Basal Insulin Therapy Among People with Type 2 Diabetes: A Retrospective Cohort Study of Costs and Patient Outcomes

Magaly Perez-Nieves et al. Diabetes Ther. 2018 Jun.

Abstract

Introduction: This research compares costs, resource utilization, and complications between adherent and nonadherent patients over the 3-year period post initiation on basal insulin therapy.

Methods: The study utilized the US-based Truven Health MarketScan® Research Databases from 2011 through 2015. Adults aged 18 years or older and identified with type 2 diabetes (T2D) who initiated therapy on basal insulin in 2012 were included. Patients were excluded if they were pregnant, filled their index basal insulin prescription via mail order, or were not continuously insured from 1 year before through 3 years following initiation of treatment with basal insulin. Instrumental variables were used to control for selection bias, and multivariable analyses were used to examine the associations between adherence to basal insulin therapy and costs, resource utilization, and acute complications.

Results: A total of 21,363 individuals were included in the study. Three years after initiating therapy on basal insulin, patients who were adherent over time to basal insulin treatment therapy (33.8% of patients) had significantly higher diabetes-related drug costs. However, patients' adherence was associated with significantly lower diabetes-related outpatient, acute care, and total costs. Results for all-cause costs were similar. Adherent patients also had significantly fewer all-cause and diabetes-related hospitalizations and emergency room visits and were significantly less likely to be diagnosed with an acute complication.

Conclusions: Results of this study illustrate that despite higher drug costs, there are disease-specific and all-cause cost offsets and improved patient outcomes associated with adherence to basal insulin therapy for people with T2D.

Funding: Eli Lilly and Company.

Keywords: Adherence; Basal insulin; Costs; Proportion of days covered; Resource utilization.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Flow diagram of inclusion–exclusion criteria and sample size
Fig. 2
Fig. 2
Diabetes-related and all-cause medical costs: adherent versus nonadherent patients. Ac1 Gycated hemoglobin, PDC Proportion of days covered
Fig. 3
Fig. 3
Likelihood of resource utilization or acute complication: adherent vs nonadherent patients. ER Emergency room
See this image and copyright information in PMC

References

    1. American Diabetes Association. Statistics about diabetes [Internet]. 2017. http://www.diabetes.org/diabetes-basics/statistics/. Accessed December 2017.
    1. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011 [Internet]. Atlanta, GA: U.S. Department of Health and Human Services, Center for Disease Control and Prevention 2011. https://www.cdc.gov/diabetes/pubs/pdf/ndfs_2011.pdf. Accessed December 2017.
    1. American Diabetes Association Economic costs of diabetes in the US in 2012. Diabetes Care. 2013;36(4):1033–1046. doi: 10.2337/dc12-2625. - DOI - PMC - PubMed
    1. American Diabetes Association 8 Pharmacologic approaches to glycemic treatment. Diabetes Care. 2018;41(Suppl 1):S73–S85. doi: 10.2337/dc18-S008. - DOI - PubMed
    1. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281(21):2005–2012. doi: 10.1001/jama.281.21.2005. - DOI - PubMed

LinkOut - more resources